We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FTIIW
251
DELISTED
FutureTech II Acquisition Corp. Warrant
FTIIW
$1.18K ﹤0.01%
30,000
– –
ECDAW
252
DELISTED
ECD Automotive Design Warrant
ECDAW
$818 ﹤0.01%
32,596
– –
TVTX icon
253
Travere Therapeutics
TVTX
$5.78B
$771 ﹤0.01%
100
– –
SBCWW
254
SBC Medical Group Warrants
SBCWW
$693 ﹤0.01%
19,800
– –
CETUR
255
DELISTED
Cetus Capital Acquisition Corp. Right
CETUR
$605 ﹤0.01%
4,999
– –
OAKUW
256
DELISTED
Oak Woods Acquisition Corp Warrant
OAKUW
$600 ﹤0.01%
30,000
– –
FLFVW
257
DELISTED
Feutune Light Acquisition Corporation Warrant
FLFVW
$510 ﹤0.01%
15,000
– –
EMCGW
258
DELISTED
Embrace Change Acquisition Corp Warrants
EMCGW
$407 ﹤0.01%
18,000
– –
FORLW
259
DELISTED
Four Leaf Acquisition Corp Warrants
FORLW
$390 ﹤0.01%
9,487
– –
AIMAW
260
DELISTED
Aimfinity Investment Corp I Warrant
AIMAW
$234 ﹤0.01%
18,000
– –
CETUW
261
DELISTED
Cetus Capital Acquisition Corp. Warrant
CETUW
$95 ﹤0.01%
5,000
– –
ABUS icon
262
CALL
Arbutus Biopharma
ABUS
$915M
– –
-177,700
Closed -$444K
ALT icon
263
PUT
Altimmune
ALT
$599M
– –
-3,900
Closed -$43.9K
ANEB
264
DELISTED
Anebulo Pharmaceuticals
ANEB
– –
-1,217
Closed -$2.94K
ANIP icon
265
ANI Pharmaceuticals
ANIP
$1.78B
– –
-2,400
Closed -$132K
ARGX icon
266
argenx
ARGX
$54.1B
– –
-70
Closed -$26.6K
ARVN icon
267
PUT
Arvinas
ARVN
$572M
– –
-800
Closed -$32.9K
AVDL
268
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-2,000
Closed -$28.2K
BCLI
269
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-6,713
Closed -$27.5K
BCYC
270
PUT
Bicycle Therapeutics
BCYC
$292M
– –
-54,100
Closed -$978K
BUR icon
271
Burford Capital
BUR
$971M
– –
-10,560
Closed -$165K
CLNN icon
272
Clene
CLNN
$67.5M
– –
-575
Closed -$3.41K
CYTK icon
273
PUT
Cytokinetics
CYTK
$10.4B
– –
-3,500
Closed -$292K
DNTH icon
274
Dianthus Therapeutics
DNTH
$6.09B
– –
-481
Closed -$5K
EYPT icon
275
PUT
EyePoint Inc
EYPT
$1.2B
– –
-800
Closed -$18.5K
9 10
11
12 13

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.